Stock ELYM ELIEM THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eliem Therapeutics, Inc.

Equities

ELYM

US28658R1068

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
6.86 USD +0.73% Intraday chart for Eliem Therapeutics, Inc. -13.05% +154.07%
08:53pm Eliem Therapeutics Insider Sold Shares Worth $338,000, According to a Recent SEC Filing MT
Jul. 01 Eliem Therapeutics, Inc.(NasdaqGM:ELYM) added to Russell Small Cap Comp Growth Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eliem Therapeutics Insider Sold Shares Worth $338,000, According to a Recent SEC Filing
Eliem Therapeutics Joining Russell 2000, 3000 Indexes
Eliem Therapeutics, Inc. Expects to Initiate Phase 2 Clinical Trials of TNT119
Eliem Therapeutics, Inc. completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.
Eliem Therapeutics, Inc. Appoints Aoife Brennan as Chief Executive Officer
Eliem Therapeutics, Inc. Announces Management Changes
Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sector Update: Health Care Stocks Softer Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Decline Thursday Afternoon
Eliem Therapeutics to Acquire Tenet Medicines; Launching Private Placement -- Eliem Shares Surge
Top Premarket Gainers
Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes
Eliem Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Harpoon Therapeutics Appoints Chief Legal Officer, Chief People Officer
Eliem Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eliem Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eliem Therapeutics Drops Kv7 Program, Explores Strategic Alternatives
Eliem Therapeutics Plans to Explore Strategic Alternatives
Eliem Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELYM Stock
  4. News Eliem Therapeutics, Inc.
  5. Other languages